novo nordisk oral semaglutide fda approval BREAKING: The has approved the first GLP-1 pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill Here's Novo Nordisk's First Oral

Though we have effective AOM in our armamentarium, such as phentermine, extended-release naltrexone and bupropion, and liraglutide, their more modest weight loss (mean total 4% to 8%) 1 and/or side-effect profiles often preclude their use

These include the appetite suppressant Mysimba (naltrexone/bupropion

Clinical symptom resolution within days of elimination suggests hereditary fructose intolerance and can be confirmed by molecular diagnosis on DNA obtained from peripheral leukocytes (68)

Without independent testing of each batch, you can't be certain what's in a given patch or that it's the same from one purchase to the next

It is a cause for awareness

This comes with risks